Last reviewed · How we verify
NCT07299799: EBP in Nursing
Evidence-Based Nursing to Reduce Adverse Events Regarding Ventilator Associated Pneumonia, Pressure Injuries and Central Line Bloodstream Infection in Intensive Care Unit in Bangladesh
NA trial testing Education with EBP in Ventilator Acquired Pneumonia in 272 participants. Not yet recruiting.
30 May 2026
Quick facts
| Lead sponsor | Hiroshima University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 272 |
| Start date | 15 February 2026 |
| Primary completion | 30 May 2026 |
| Estimated completion | 30 May 2026 |
| Sites | 2 locations across Bangladesh, Japan |
Drugs / interventions tested
- Education with EBP
- This is a pre- and post- quasi-experimental study.
Conditions studied
- Ventilator Acquired Pneumonia — all drugs for Ventilator Acquired Pneumonia →
- Central Line Associated Blood Stream Infections (CLABSI) — all drugs for Central Line Associated Blood Stream Infections (CLABSI) →
- Pressure Ulcer (PU) — all drugs for Pressure Ulcer (PU) →
- Medical Device Related Pressure Ulcer (MDRPU) — all drugs for Medical Device Related Pressure Ulcer (MDRPU) →
Sponsor
Hiroshima University
Who can join
18 and older, any sex, with Ventilator Acquired Pneumonia or Central Line Associated Blood Stream Infections (CLABSI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Quality of care is crucial for preventing adverse events such as infection in the intensive care units (ICUs). The most common ICU-acquired infections include pneumonia such as Ventilator Associated Pneumonia (VAP), Pressure Ulcer (PU), Medical Device Related Pressure Ulcer (MDRPU), and Central Line-Associated Bloodstream Infection (CLABSI). VAP, PU, and MDRPU are significant indicators of the quality of care, while CLABSI is a critical marker of healthcare quality in ICUs, as it is largely preventable through strict adherence to infection control protocols. VAP is a lung infection that occurs in patients receiving mechanical ventilation for more than 48 hours. A PU is defined as localized damage to the skin or underlying tissue caused solely by pressure, while MDRPUs may also result from friction or pressure from medical devices or other objects. CLABSI is a severe infection caused by improperly inserted or maintained central venous catheters, which underscores the need for stringent catheter management protocols.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07299799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Education with EBP
Trials testing the same drug.
- NCT06624540 — Effect of Implementing Evidence-based Practice and Nurse's Behavior Change on Quality of Care in Intensive Care Unit: Fo · NA · recruiting
Other Hiroshima University trials
Trials by the same sponsor.
- NCT07527429 — Procedure Manual-Based Simulation Training to Improve Operating Room Nurses' Core Competencies · NA · not yet recruiting
- NCT07384650 — Post-stroke Nurse-led Rehabilitation to Improve Functional Activity and Community Participation in Bangladesh · NA · recruiting
- NCT07310680 — Impact of mHealth Education on Hemoglobin Level Among Pregnant Women With Anemia in Rural Bangladesh. · NA · not yet recruiting
- NCT06871553 — The Self-management Program on Hemodialysis Patients in Cambodia · NA · completed
- NCT06786559 — Nurse-led Rehabilitation to Improve Self-care Among Stroke Patients in Bangladesh · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07299799 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hiroshima University
- Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07299799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing